Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06375239 · ClinicalTrials.gov registry record
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
A clinical trial of Retinitis Pigmentosa and Stargardt Disease, sponsored by Ray Therapeutics.
- Recruiting
- Registry status
- 120
- Enrollment target
- 1
- Study location
NCT06375239 is a study of Retinitis Pigmentosa and Stargardt Disease that is actively recruiting participants, run by Ray Therapeutics. The registered enrollment target is 120 participants, below the 258-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06375239, a study of Retinitis Pigmentosa and Stargardt Disease, is actively recruiting participants, sponsored by Ray Therapeutics.
- RECRUITING
- Registry status
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision. The mission of the VRAI is to enable the highest quality, standardized efficacy testing of patients with visual impairment. The VRAI facilitates the development and refinement of existing endpoints specifically for testing patients with Low Vision.
Conditions Studied
Study Locations (1)
California
- Vision Research and Assessment Institute - Irvine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-04-05 |
| Est. Completion | 2026-04-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06375239
The ClinicalTrials.gov registry entry for NCT06375239 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 258-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (53% lower). The listed sponsor is Ray Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Retinitis Pigmentosa appearing as the primary indexed condition, and to 0 interventions.
NCT06375239 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06375239 about?
NCT06375239 is a clinical study titled "Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration". The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision. The mission of the VRAI is to enable the highest quality, standardized efficacy testing of patients with visual impairment. The...
What is the current status of trial NCT06375239?
This trial is currently recruiting. The enrollment target is 120 participants. The study started on 2024-04-05. Estimated completion is 2026-04-30.
What conditions does trial NCT06375239 study?
This clinical trial studies the following conditions: Retinitis Pigmentosa, Stargardt Disease, Retinal Dystrophies, Choroideremia, Stargardt Macular Dystrophy.
Who is sponsoring clinical trial NCT06375239?
This trial is sponsored by Ray Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06375239 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinitis Pigmentosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Promising ROd-cone DYstrophy Gene therapY
RECRUITING · Phase 1
-
High Resolution Retinal Imaging
RECRUITING
-
Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
RECRUITING · Phase 2
-
Retinal Imaging in Patients With Inherited Retinal Degenerations
RECRUITING
-
Cell Collection to Study Eye Diseases
RECRUITING
-
Adaptive Optics Imaging of Outer Retinal Diseases
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.